Does MiECC Improve Outcome in Diabetic Patients Undergoing Elective Coronary Bypass Grafting?
Launched by HERZZENTRUM COSWIG · Feb 1, 2016
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
Cardiopulmonary bypass (CPB) is known having a negative influence referring to systemic inflammatory reaction after cardiac surgery which can cause acute kidney injury (AKI). Miniaturized extracorporeal circulation (MECC) attempts to reduce the adverse effects of conventional extracorporeal circulation bypass. Finally, AKI after CPB is a significant clinical problem that increasingly complicates the course of hospitalization and clinical outcome.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diabetes mellitus type 2
- • isolated elective coronary revascularization
- Exclusion Criteria:
- • urgent or emergent Status
- • Re-Operation
- • preexisting reanimation
- • preexisting renal transplantation
- • chronic kidney insufficiency (GFR \< 30 ml/min)
- • renal cell carcinoma
- • renal artery Stenosis
- • heart valve disease (middle- and high-grade)
- • endocarditis
- • infections (HIV, Tbc and all types of Hepatitis)
- • hepatic cirrhosis
About Herzzentrum Coswig
Herzzentrum Coswig is a leading clinical research organization dedicated to advancing cardiac care through innovative clinical trials and research initiatives. With a focus on cardiovascular health, the center is committed to investigating novel therapies and treatment modalities that enhance patient outcomes. Leveraging a multidisciplinary team of experienced healthcare professionals and state-of-the-art facilities, Herzzentrum Coswig fosters collaboration with academic institutions and industry partners to drive scientific discovery and improve the quality of life for individuals with heart conditions. Their rigorous adherence to ethical standards and regulatory compliance ensures the integrity and reliability of their research findings.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials